RATIONALE: Collaterals lessen tissue injury in occlusive disease. However, aging causes progressive decline in their number and smaller diameters in those that remain (collateral rarefaction), beginning at 16 months of age in mice (i.e., middle age), and worse ischemic injury-effects that are accelerated in even 3-month-old eNOS(-/-) mice. These findings have found indirect support in recent human studies. OBJECTIVE: We sought to determine whether other cardiovascular risk factors (CVRFs) associated with endothelial dysfunction cause collateral rarefaction, investigate possible mechanisms, and test strategies for prevention. METHODS AND RESULTS: Mice with nine different models of CVRFs of 4-12 months of age were assessed for number and diameter of native collaterals in skeletal muscle and brain and for collateral-dependent perfusion and ischemic injury after arterial occlusion. Hypertension caused collateral rarefaction whose severity increased with duration and level of hypertension, accompanied by greater hindlimb ischemia and cerebral infarct volume. Chronic treatment of wild-type mice with L-N (G)-nitro-arginine methylester caused similar rarefaction and worse ischemic injury which were not prevented by lowering arterial pressure with hydralazine. Metabolic syndrome, hypercholesterolemia, diabetes mellitus, and obesity also caused collateral rarefaction. Neither chronic statin treatment nor exercise training lessened hypertension-induced rarefaction. CONCLUSION: Chronic CVRF presence caused collateral rarefaction and worse ischemic injury, even at relatively young ages. Rarefaction was associated with increased proliferation rate of collateral endothelial cells, effects that may promote accelerated endothelial cell senescence.
RATIONALE: Collaterals lessen tissue injury in occlusive disease. However, aging causes progressive decline in their number and smaller diameters in those that remain (collateral rarefaction), beginning at 16 months of age in mice (i.e., middle age), and worse ischemic injury-effects that are accelerated in even 3-month-old eNOS(-/-) mice. These findings have found indirect support in recent human studies. OBJECTIVE: We sought to determine whether other cardiovascular risk factors (CVRFs) associated with endothelial dysfunction cause collateral rarefaction, investigate possible mechanisms, and test strategies for prevention. METHODS AND RESULTS:Mice with nine different models of CVRFs of 4-12 months of age were assessed for number and diameter of native collaterals in skeletal muscle and brain and for collateral-dependent perfusion and ischemic injury after arterial occlusion. Hypertension caused collateral rarefaction whose severity increased with duration and level of hypertension, accompanied by greater hindlimb ischemia and cerebral infarct volume. Chronic treatment of wild-type mice with L-N (G)-nitro-arginine methylester caused similar rarefaction and worse ischemic injury which were not prevented by lowering arterial pressure with hydralazine. Metabolic syndrome, hypercholesterolemia, diabetes mellitus, and obesity also caused collateral rarefaction. Neither chronic statin treatment nor exercise training lessened hypertension-induced rarefaction. CONCLUSION: Chronic CVRF presence caused collateral rarefaction and worse ischemic injury, even at relatively young ages. Rarefaction was associated with increased proliferation rate of collateral endothelial cells, effects that may promote accelerated endothelial cell senescence.
Authors: Nathalie Kubis; Sandrine Besnard; Jean-Sébastien Silvestre; Michel Feletou; Paul L Huang; Bernard I Lévy; Alain Tedgui Journal: J Hypertens Date: 2002-02 Impact factor: 4.844
Authors: Hans-Christian Koennecke; W Belz; D Berfelde; M Endres; S Fitzek; F Hamilton; P Kreitsch; B-M Mackert; D G Nabavi; C H Nolte; W Pöhls; I Schmehl; B Schmitz; M von Brevern; G Walter; P U Heuschmann Journal: Neurology Date: 2011-08-24 Impact factor: 9.910
Authors: E G Shesely; N Maeda; H S Kim; K M Desai; J H Krege; V E Laubach; P A Sherman; W C Sessa; O Smithies Journal: Proc Natl Acad Sci U S A Date: 1996-11-12 Impact factor: 11.205
Authors: Wojciech Rzechorzek; Hua Zhang; Brian K Buckley; Kunjie Hua; Daniel Pomp; James E Faber Journal: J Cereb Blood Flow Metab Date: 2017-07-07 Impact factor: 6.200
Authors: Jennifer L Lucitti; Robert Sealock; Brian K Buckley; Hua Zhang; Lin Xiao; Andrew C Dudley; James E Faber Journal: Stroke Date: 2016-11-03 Impact factor: 7.914
Authors: D D Quintana; S E Lewis; Y Anantula; J A Garcia; S N Sarkar; J Z Cavendish; C M Brown; J W Simpkins Journal: Neuroimage Date: 2019-08-22 Impact factor: 6.556
Authors: Costantino Iadecola; Kristine Yaffe; José Biller; Lisa C Bratzke; Frank M Faraci; Philip B Gorelick; Martha Gulati; Hooman Kamel; David S Knopman; Lenore J Launer; Jane S Saczynski; Sudha Seshadri; Adina Zeki Al Hazzouri Journal: Hypertension Date: 2016-10-10 Impact factor: 10.190
Authors: Jesús M Pradillo; Macarena Hernández-Jiménez; María E Fernández-Valle; Violeta Medina; Juan E Ortuño; Stuart M Allan; Spencer D Proctor; Juan M Garcia-Segura; María J Ledesma-Carbayo; Andrés Santos; María A Moro; Ignacio Lizasoain Journal: J Cereb Blood Flow Metab Date: 2020-12-01 Impact factor: 6.200